Cardlytics sees $118,071 in stock sales by major shareholder Clifford Sosin By Investing.com

In the most recent transactions filed with the Securities and Exchange Commission, Clifford Sosin, a significant shareholder of Cardlytics, Inc. (NASDAQ:), sold 31,300 shares of the company’s common stock on December 30 and 31, 2024 with share prices ranging from $3.7661 to $3.7784 118,071 USD. The sell-off comes as Cardlytics trades near $3.73, well below its 52-week high of $20.52 InvestingPro: on analysis, the stock looks slightly undervalued despite significant challenges with its debt load.

Following these sales, Sosin indirectly retains ownership of 6,368,910 shares through Sosin Master, LP and CSWR Partners, LP.In addition, it holds $21.3 million in principal amount of Cardlytics’ 4.25% Convertible Senior Notes. which is due in 2029. one $1,000 principal amount, although the issuer may choose to convert in cash, stock, or a combination of the two. With a market capitalization of $189.57 million and total debt of $221.94 million, InvestingPro: Subscribers can access 10 additional key insights into Cardlytics’ financial health and future prospects via a comprehensive Pro Research Report.

In other recent news, Cardlytics reported Q3 2024 financial results, highlighting its expectations for improved performance in Q4. The company outlined plans to establish new partnerships with financial institutions and implement operational and product improvements, however , which are subject to risks that could affect actual results. Cardlytics has acknowledged these potential risk factors while expressing optimism about the Company’s financial performance for the coming quarter also expects the introduction of new partnerships and the introduction of operational and product initiatives to strengthen its position in the market. Detailed financial information, including non-GAAP measures, can be found in the company’s latest press release and SEC filings is to oversee Cardlytics’ progress in these areas.

This article is powered by AI and reviewed by an editor. See our T&C for more information.